Literature DB >> 20148295

Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.

Karen A Lewis1, Arynn Yaeger, George N DeMartino, Philip J Thomas.   

Abstract

A hallmark of Parkinson disease (PD) is the formation of intracellular protein inclusions called Lewy bodies that also contain mitochondria. alpha-Synuclein (alpha Syn) is a major protein component of Lewy bodies, where it is in an amyloid conformation and a significant fraction is truncated by poorly understood proteolytic events. Previously, we demonstrated that the 20S proteasome cleaves alpha Syn in vitro to produce fragments like those observed in Lewy bodies and that the fragments accelerate the formation of amyloid fibrils from full-length alpha Syn. Three point mutations in alpha Syn are associated with early-onset familial PD: A30P, E46K, and A53T. However, these mutations have very different effects on the amyloidogenicity and vesicle-binding activity of alpha Syn, suggesting neither of these processes directly correlate with neurodegeneration. Here, we evaluate the effect of the disease-associated mutations on the fragmentation, conformation, and association reactions of alpha Syn in the presence of the 20S proteasome and liposomes. The 20S proteasome produced the C-terminal fragments from both the mutant and wildtype alpha Syn. These truncations accelerated fibrillization of all alpha-synucleins, but again there was no clear correlation between the PD-associated mutations and amyloid formation in the presence of liposomes. Recent data suggests that cellular toxicity is caused by a soluble oligomeric species, which is a precursor to the amyloid form and is immunologically distinguishable from both soluble monomeric and amyloid forms of alpha Syn. Notably, the rate of formation of the soluble, presumptively cytotoxic oligomers correlated with the disease-associated mutations when both 20S proteasome and liposomes were present. Under these conditions, the wildtype protein was also cleaved and formed the oligomeric structures, albeit at a slower rate, suggesting that 20S-mediated truncation of alpha Syn may play a role in sporadic PD as well. Evaluation of the biochemical reactions of the PD-associated alpha-synuclein mutants in our in vitro system provides insight into the possible pathogenetic mechanism of both familial and sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148295      PMCID: PMC3266686          DOI: 10.1007/s10863-009-9258-y

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  70 in total

1.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

2.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

3.  Structure and dynamics of micelle-bound human alpha-synuclein.

Authors:  Tobias S Ulmer; Ad Bax; Nelson B Cole; Robert L Nussbaum
Journal:  J Biol Chem       Date:  2004-12-22       Impact factor: 5.157

4.  Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

Authors:  Masaki Wakamatsu; Aiko Ishii; Shingo Iwata; Junko Sakagami; Yuriko Ukai; Mieko Ono; Daiji Kanbe; Shin-ichi Muramatsu; Kazuto Kobayashi; Takeshi Iwatsubo; Makoto Yoshimoto
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

5.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

6.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

Authors:  C M van Duijn; M C Dekker; V Bonifati; R J Galjaard; J J Houwing-Duistermaat; P J Snijders; L Testers; G J Breedveld; M Horstink; L A Sandkuijl; J C van Swieten; B A Oostra; P Heutink
Journal:  Am J Hum Genet       Date:  2001-07-02       Impact factor: 11.025

7.  Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.

Authors:  Jie Li; Vladimir N Uversky; Anthony L Fink
Journal:  Neurotoxicology       Date:  2002-10       Impact factor: 4.294

8.  Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.

Authors:  P J Kahle; M Neumann; L Ozmen; V Muller; H Jacobsen; A Schindzielorz; M Okochi; U Leimer; H van Der Putten; A Probst; E Kremmer; H A Kretzschmar; C Haass
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

9.  Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

Authors:  George K Tofaris; Pablo Garcia Reitböck; Trevor Humby; Sarah L Lambourne; Mark O'Connell; Bernardino Ghetti; Helen Gossage; Piers C Emson; Lawrence S Wilkinson; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

10.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

View more
  9 in total

1.  Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology.

Authors:  Karen A Lewis; Yang Su; Olina Jou; Caroline Ritchie; Chan Foong; Linda S Hynan; Charles L White; Philip J Thomas; Kimmo J Hatanpaa
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

Review 2.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 3.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

4.  N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42.

Authors:  Olga Szczepankiewicz; Björn Linse; Georg Meisl; Eva Thulin; Birgitta Frohm; Carlo Sala Frigerio; Michael T Colvin; Angela C Jacavone; Robert G Griffin; Tuomas Knowles; Dominic M Walsh; Sara Linse
Journal:  J Am Chem Soc       Date:  2015-11-17       Impact factor: 15.419

5.  Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.

Authors:  Wei Wang; Linh T T Nguyen; Christopher Burlak; Fariba Chegini; Feng Guo; Tim Chataway; Shulin Ju; Oriana S Fisher; David W Miller; Debajyoti Datta; Fang Wu; Chun-Xiang Wu; Anuradha Landeru; James A Wells; Mark R Cookson; Matthew B Boxer; Craig J Thomas; Wei Ping Gai; Dagmar Ringe; Gregory A Petsko; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

6.  Mechanisms of protein oligomerization: inhibitor of functional amyloids templates α-synuclein fibrillation.

Authors:  Istvan Horvath; Christoph F Weise; Emma K Andersson; Erik Chorell; Magnus Sellstedt; Christoffer Bengtsson; Anders Olofsson; Scott J Hultgren; Matthew Chapman; Magnus Wolf-Watz; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  J Am Chem Soc       Date:  2012-02-09       Impact factor: 15.419

Review 7.  Alpha-synuclein oligomers: a new hope.

Authors:  Nora Bengoa-Vergniory; Rosalind F Roberts; Richard Wade-Martins; Javier Alegre-Abarrategui
Journal:  Acta Neuropathol       Date:  2017-08-12       Impact factor: 17.088

Review 8.  α-Synuclein: the long distance runner.

Authors:  Sonia George; Nolwen L Rey; Nicole Reichenbach; Jennifer A Steiner; Patrik Brundin
Journal:  Brain Pathol       Date:  2013-05       Impact factor: 6.508

9.  Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice.

Authors:  Margot Fournier; Amandine Roux; Jérôme Garrigue; Marie-Paule Muriel; Paul Blanche; Hilal A Lashuel; John P Anderson; Robin Barbour; Jiping Huang; Sophie Tezenas du Montcel; Alexis Brice; Olga Corti
Journal:  BMC Neurosci       Date:  2013-11-05       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.